Shares of Tekmira (TSX:TKM, Nasdaq:TKMR) are soaring in after market trading after news broke of the first diagnosis of Ebola in the United States. A patient at Dallas’s Texas Health Presbyterian Hospital has tested positive for Ebola, and is currently being treated. The Centers for Disease Control and Prevention this afternoon confirmed that the infected […]
Archives for September 2014
Horan: “I don’t see any other stock growing like these guys.”
Driven in part by recent distribution and M&L deals for brands like Teletubbies and Yo Gabba Gabba!, DHX Media will double its revenue in fiscal 2015, says analyst Dev Bhangui.
The acquisition price for one of its immediate peers suggests Cynapsus Therapeutics (TSXV:CTH) is currently undervalued, says Daniel Pearlstein.
When Stewart Butterfield developed Flickr through his old company Ludicorp in Vancouver, he probably didn’t imagine he’d sell it to Yahoo in 2005. Likewise, he probably didn’t expect he would have developed the most hyped business collaboration app in recent memory, called Slack, via failing at a much beloved multi-player video game, called Glitch. And […]
Its prospects for growth, both organically and through M&A, combined with an able management team make Intertain Group (TSX:IT) an attractive investment, says Mackie Research Capital analyst Nikhil Thadani. In a research report to clients last Thursday, Thadani initiated coverage of Intertain Group with a “Buy” rating and one-year target of $14.00, implying a return […]
Manhattan Venture Partners Chief Economist Max Wolff thinks BlackBerry CEO John Chen has done a good job at refocusing the company’ efforts towards is strengths which, increasingly, are not in producing handsets.
QHR Corp’s (TSXV:QHR) recent regulatory clearance in Ontario is another positive for the company, says Haywood analyst Massimo Voci.
This has been another very slow tech news week. News was dominated by the fawning (and not so fawning) reviews of the iPhone 6, and, in particular, the ‘Mr. Gumby’ bendyness users complained about. As is typical with Apple, they seem to have used their marketing prowess to get ahead of the story, and this […]
Back when I was a drug rep, I spent a few days shadowing a cardiologist and was fortunate to spend some time in the cardiac catheterization lab (cath lab). Those were the heady days of drug eluding stents, where companies like Angiotech were soaring on the wide utilization of stents for coronary artery disease. Things […]